Citadel Advisors
VIRX

Citadel Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Citadel Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,800
Closed -$290 – 15997
2024
Q4 		$290 Buy
+1,800
New +$354 ﹤0.01% 14354
2024
Q3 		– Sell
-10,900
Closed -$5.93K – 15509
2024
Q2 		$5.93K Buy
10,900
+5,000
+85% +$3.94K ﹤0.01% 13369
2024
Q1 		$6.02K Buy
5,900
+4,800
+436% +$3.51K ﹤0.01% 13704
2023
Q4 		$627 Sell
1,100
-300
-21% -$184 ﹤0.01% 13983
2023
Q3 		$1.46K Sell
1,400
-1,400
-50% -$1.9K ﹤0.01% 13866
2023
Q2 		$3.95K Buy
2,800
+2,200
+367% +$3.15K ﹤0.01% 13642
2023
Q1 		$954 Sell
600
-21,140
-97% -$38.4K ﹤0.01% 14392
2022
Q4 		$31.7K Sell
21,740
-44,700
-67% -$131K ﹤0.01% 12669
2022
Q3 		$284K Sell
66,440
-19,700
-23% -$83.4K ﹤0.01% 9705
2022
Q2 		$334K Sell
86,140
-19,800
-19% -$56.4K ﹤0.01% 9580
2022
Q1 		$504K Buy
+105,940
New +$319K ﹤0.01% 9377
2021
Q1 		– Sell
-7,883
Closed -$55K – 13827
2020
Q4 		$55K Buy
+7,883
New +$41.1K ﹤0.01% 10535
2020
Q3 		– Sell
-1,214
Closed -$11K – 10884
2020
Q2 		$11K Buy
1,214
+914
+305% +$13.8K ﹤0.01% 9626
2020
Q1 		$4K Sell
300
-329
-52% -$7.14K ﹤0.01% 9500
2019
Q4 		$7K Sell
629
-551
-47% -$9.23K ﹤0.01% 9018
2019
Q3 		$30K Buy
1,180
+554
+88% +$16K ﹤0.01% 8848
2019
Q2 		$16K Sell
626
-251
-29% -$9.71K ﹤0.01% 8979
2019
Q1 		$37K Sell
877
-40
-4% -$906 ﹤0.01% 8935
2018
Q4 		$13K Buy
917
+308
+51% +$12.6K ﹤0.01% 8875
2018
Q3 		$43K Buy
609
+78
+15% +$5.92K ﹤0.01% 8834
2018
Q2 		$39K Buy
531
+177
+50% +$15.8K ﹤0.01% 8490
2018
Q1 		$34K Buy
+354
New +$60.7K ﹤0.01% 8023
2016
Q3 		– Sell
-105
Closed -$12K – 7888
2016
Q2 		$12K Buy
105
+45
+75% +$4.99K ﹤0.01% 6714
2016
Q1 		$7K Sell
60
-9
-13% -$1.36K ﹤0.01% 6616
2015
Q4 		$13K Buy
69
+18
+35% +$3.37K ﹤0.01% 8183
2015
Q3 		$9K Buy
51
+15
+42% +$5.41K ﹤0.01% 8506
2015
Q2 		$23K Sell
36
-115
-76% -$61.1K ﹤0.01% 8087
2015
Q1 		$78K Buy
151
+42
+39% +$21.2K ﹤0.01% 7056
2014
Q4 		$58K Sell
109
-759
-87% -$342K ﹤0.01% 7086
2014
Q3 		$1.3M Buy
868
+748
+623% +$1.08M ﹤0.01% 3379
2014
Q2 		$164K Buy
120
+43
+56% +$49.9K ﹤0.01% 5777
2014
Q1 		$106K Buy
+77
New +$89.5K ﹤0.01% 6145

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $448M AUM 50.36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Citadel Advisors's VIRX Position: Q1 2025 in Review

Citadel Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 1,626,258 shares — an estimated $262K sold.

Citadel Advisors first reported a position in VIRX in Q1 2014 and held it in 35 quarters. The position peaked at $23.3M in Q3 2014. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Citadel Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,626,258 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $262K.
  • Citadel Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 35 quarters.
  • Citadel Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $23.3M in Q3 2014.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.